Articles related to CLINICAL TRIALS

According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.

The median time to recovery in a group of 1,800 vaccinated and unvaccinated adults (median age: 48 years) was essentially the same whether the patients received ivermectin or placebo: 12 and 13 days, respectively. Death rate was slightly higher in the ivermectin group and rates of pneumonia and VTE were slightly higher in the placebo group.

After supporting a number of significant clinical trials in psychiatry more than ten years ago, NIMH abruptly shifted its approach and began allocating 90% of its money to neuroscience. The policy is still in place even though this “has yet to deliver major clinical gains.” Clinical advancement has been halted as a result of the devaluation of mental clinical trials and the meticulously designed, essential methodologies they demand.

The FOENIX*-CCA2 trial, a global phase 2, open-label trial examining 103 patients with unresectable, locally progressed, or metastatic iCCA harboring FGFR2 gene rearrangements including fusions, was the basis for the approval of futibatinib (Lytgobi, Taiho Oncology). Patients in this trial received 20 mg of futibatinib orally once daily until disease progression or intolerable toxicity; the primary end goal was achieved with a 42% objective response rate as determined by an impartial central evaluation. With 72% of responses lasting at least six months, the median response time was 9.7 months.

Radiation field size and the effects of ADT sequencing for various oncologic end goals interact significantly. Concurrent/adjuvant ADT was linked to considerably better metastasis-free survival, prostate cancer-specific mortality, and overall survival with prostate-only radiation; the impact of ADT sequencing with whole-pelvic radiation is less clear, with neither consistently showing a benefit.

The MajesTEC-1 trial, a phase 1/2 open-label research that revealed effectiveness data from 110 patients with relapsed or refractory multiple myeloma, provided evidence from strong response rates that served as the foundation for the approval. The accelerated approval of a bispecific antibody for the incurable blood malignancy is a first of its kind in the US. Proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody must have been used in prior therapy.